实体瘤的过继性细胞疗法：黑色素瘤的现状及下一代疗法
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
作者信息
Haanen John, Los Christy, Phan Giao Q, Betof Warner Allison
机构信息
Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
出版信息
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431608. doi: 10.1200/EDBK_431608.
PMID:38776509
Abstract
Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other upcoming new cell therapies.
摘要
利菲鲁塞（Lifileucel）或肿瘤浸润淋巴细胞（TIL）最近已获得美国食品药品监督管理局（FDA）批准，用于转移性黑色素瘤患者，作为实体瘤的首个细胞疗法。我们讨论了将肿瘤浸润淋巴细胞作为新的标准治疗方案（SOC）的推广以及其他即将出现的新细胞疗法。
Zotero 插件